Skip to main content
Premium Trial:

Request an Annual Quote

Leena Peltonen, Cathy Burzik, Timothy Rink, Mahasti Afshar, Chris van Ingen

Leena Peltonen is joining the Wellcome Trust Sanger Institute as head of human genetics this month. Until now, she was professor of medical genetics and molecular medicine at the University of Helsinki and chair of the department of molecular medicine at the National Public Health Institute of Finland. She has been a visiting professor at the Broad Institute since 2005. From 1998 until 2002, she was chair of human genetics at the University of California Los Angeles. Peltonen pioneered the use of special population resources in disease gene hunts, especially using Finnish populations. She is a member of the Finnish and US National Academy of Sciences and was president of the Human Genome Organization from 2005 until 2007. She will keep a part-time affiliation with the University of Helsinki and the National Public Health Institute. Peltonen holds MD and PhD degrees from the University of Oulu in Finland.

Cathy Burzik is one of three new members on the board of trustees of the Keck Graduate Institute, KGI said last month. She is the CEO of Kinetic Concepts and was previously president of Applied Biosystems.

Timothy Rink has joined the board of directors of Adnexus Therapeutics, the company said last month. He is also chairman of the strategy panel of the technology transfer division of the Wellcome Trust and on the board of other firms. Previously, Rink was chairman of Solexa. In the past, he was chairman and CEO of Aurora Biosciences. As an associate professor at the University of Cambridge, he studied cell signaling. Rink obtained his undergraduate and postgraduate scientific and medical degrees at the University of Cambridge and UniversityCollege Hospital, London.

Mahasti Afshar has become vice president of alliances for the X Prize Foundation, the organization said last month. In her new position, she will “form relationships with visionary individuals and organizations” that “share the foundation's goal of spurring revolution through competition,” according to the foundation. Afshar comes to the X Prize Foundation from the Los Angeles Philharmonic Association, where she was director of endowment. She holds a PhD in Sanskrit and Indo-European folklore and mythology from Harvard University. The Archon X Prize for Genomics was launched in Oct. 2006 and seeks to award $10 million to the first team to map 100 human genomes in 10 days for less than $10,000 each.

Chris van Ingen will retire from Agilent Technologies on Oct. 31, the company said last month. He is president of Agilent’s bio-analytical measurement business. Van Ingen, who is 61, spent 30 years at Agilent and Hewlett-Packard, which he joined in 1977 as a sales engineer in the Netherlands.
Agilent also said last week that Bill Molnar has become vice president and general manager of Stratagene, a company division that Agilent acquired for its bio-analytical measurement business this summer. Most recently, Molnar was vice president and general manager of EMD Chemicals' lab business. Molnar holds an MBA in finance/industrial marketing from Loyola College, a master's degree in chemical engineering from Carnegie Mellon University, and a bachelor's degree in chemistry from Bethany College.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.